TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7609516

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lacidipine 8 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lacidipine (all doses)
Number of subjects: 17
Study: 3129313

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) pulsatile LH‐RH therapy (50 to 100 ng/kg body weight/90 to 120 minutes)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Naloxone administration (2 mg IV bolus plus 4 mg infusion lasting 120 minutes)
Number of subjects: 5
Study: 29662493

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum bv. infantis CCUG 52486 combined with gluco-oligosaccharide (B. longum + Gl-OS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28038841

Group type: EXPERIMENTAL
Intervention: OKd (discontinued ortho-k lens wear for 7 months, then resumed for 7 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: OKc (continued ortho-k lens wear throughout the study)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (continued wearing spectacles)
Number of subjects: 44
Study: 24297383

Group type: EXPERIMENTAL
Intervention: Erythrocyte-methotrexate-polyglutamate (MTX-PG) concentrations
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: MTX-PG1, MTX-PG2, MTX-PG3, total MTX-PG
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: MTX-PG2, MTX-PG3, MTX-PG4, total MTX-PG
Number of subjects: 387
Study: 23948835

Group type: EXPERIMENTAL
Intervention: Deep cross-friction treatment on the thoraco-lumbar Erector spinae and gluteals, 30 minutes, two sessions per week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 20980977

Group type: EXPERIMENTAL
Intervention: Low protein intake (0.58 g/kg per day)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Usual protein intake (1.3 g/kg per day)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Very low protein intake (0.28 g/kg per day)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Low protein intake (0.58 g/kg per day) in study B
Number of subjects: 741
Study: 18093273

Group type: EXPERIMENTAL
Intervention: Protocol biopsies at 1 and 3 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (indicated biopsies only)
Number of subjects: 102
Study: 16441798

Group type: EXPERIMENTAL
Intervention: Rapid Rhino Riemann pack
Number of subjects: 45

Group type: COMPARATOR
Intervention: Telfa pack
Number of subjects: 45
Study: 12895183

Group type: EXPERIMENTAL
Intervention: Ciclopirox gel 0.77% applied twice daily for 28 days
Number of subjects: 178

Group type: COMPARATOR
Intervention: Vehicle applied twice daily for 28 days
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ciclopirox gel 0.77%
Number of subjects: 178

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 178
Study: 10618300

Group type: EXPERIMENTAL
Intervention: Surgical repair (n=34)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Medical treatment (n=35)
Number of subjects: 84

Group type: COMPARATOR
Intervention: VSD patients
Number of subjects: 84
Study: 8704066

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 1315644

Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions of 30 min cycling at 70% of maximal capacity for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 10
Study: 3910771

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily (group CD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Previous regimen (beta-blockers and diuretics) (group BD)
Number of subjects: 34
Study: 31155159

Group type: EXPERIMENTAL
Intervention: Classroom lectures
Number of subjects: 131

Group type: COMPARATOR
Intervention: Simulation course
Number of subjects: 131
Study: 28807519

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity social concerns
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity cognitive concerns
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Inhibitory intolerance of uncertainty
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Negative affect (NA)
Number of subjects: 298
Study: 26656672

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (four 30-min behavioral counseling sessions)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 131
Study: 23572043

Group type: EXPERIMENTAL
Intervention: Minimal debridement technique
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 47
Study: 22053921

Group type: EXPERIMENTAL
Intervention: Synchronous event schedule (temporally regular)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asynchronous event schedule (temporally irregular)
Number of subjects: 0
Study: 20439197

Group type: EXPERIMENTAL
Intervention: Cetuximab/docetaxel/gemcitabine
Number of subjects: 69
Study: 18616366

Group type: EXPERIMENTAL
Intervention: Midface advancement by osteotomy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Midface advancement by distraction
Number of subjects: 15
Study: 16115108

Group type: EXPERIMENTAL
Intervention: Malassezia colonisation
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Candida colonisation
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Malassezia and Candida co-colonisation
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Saccharomyces colonisation
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Malassezia furfur
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Candida albicans
Number of subjects: 245
Study: 11834133

Group type: EXPERIMENTAL
Intervention: 2.5 mg of tibolone, taken daily for 12 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo pills, taken daily for 12 months
Number of subjects: 85
Study: 11300380

Group type: EXPERIMENTAL
Intervention: Olprinone 0.2 microg x kg(‐1) x min(‐1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Olprinone 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9002565

Group type: EXPERIMENTAL
Intervention: Physician visual assessment
Number of subjects: 3949

Group type: COMPARATOR
Intervention: Not seen by EP
Number of subjects: 3949

Group type: COMPARATOR
Intervention: All RN triage
Number of subjects: 3949

Group type: EXPERIMENTAL
Intervention: Seen by EP
Number of subjects: 3949

Group type: EXPERIMENTAL
Intervention: Triage categories visualized by EP
Number of subjects: 3949

Group type: COMPARATOR
Intervention: Triage categories not visualized by EP
Number of subjects: 3949
Study: 8510513

Group type: EXPERIMENTAL
Intervention: Intralipid 10% (0.3 g triglyceride [TG]/kg/h for 6 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lipidem (0.1 g/kg/h for 6 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both emulsions infused in random order (0.1 g/kg/h for 6 hours)
Number of subjects: 10
Study: 3525430

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 384
Study: 29665518

Group type: EXPERIMENTAL
Intervention: IPSRT + DIR
Number of subjects: 42

Group type: COMPARATOR
Intervention: DIR-alone
Number of subjects: 42
Study: 28446441

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine (3.75 μg HA)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine (15 μg HA)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine (3.75 μg HA)
Number of subjects: 261
Study: 26521019

Group type: COMPARATOR
Intervention: Lurasidone 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lurasidone 80 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23578605

Group type: EXPERIMENTAL
Intervention: ITCA 650 (10, 20, 40, or 80 μg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ITCA 650 (40 and 80 μg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ITCA 650
Number of subjects: 44
Study: 21178082

Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg/d from wk 20 of gestation through delivery)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 739
Study: 18280336

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 16547162

Group type: EXPERIMENTAL
Intervention: Probabilistic categorization strategy analysis
Number of subjects: 0
Study: 12488300

Group type: EXPERIMENTAL
Intervention: Gemcitabine alone (2,200 mg/m² biweekly)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Gemcitabine plus capecitabine (2,200 mg/m² gemcitabine biweekly + 2,500 mg/m² capecitabine days 1-7)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Number of subjects: 83

Group type: COMPARATOR
Intervention: Gemcitabine plus capecitabine
Number of subjects: 83
Study: 11082090

Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 100
Study: 9367703

Group type: EXPERIMENTAL
Intervention: Org 2766 (2 mg)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Org 2766 (4 mg)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 1552746

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX, 1 g/m2)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Cranial irradiation and intrathecal MTX
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Teniposide/cytarabine and delayed cranial irradiation
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Successful remission retrieval therapy
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Total long-term survivors
Number of subjects: 427
Study: 31172107

Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine (PK)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Propofol-Fentanyl (PF)
Number of subjects: 110
Study: 27180101

Group type: EXPERIMENTAL
Intervention: Intramedullary implant
Number of subjects: 91

Group type: COMPARATOR
Intervention: Kirschner wire
Number of subjects: 91
Study: 26391465

Group type: COMPARATOR
Intervention: Monthly dosing of intravitreal 0.5 mg ranibizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treat-and-extend (TREX) management strategy
Number of subjects: 60
Study: 23753091

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study: 21961463

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study: 19999191

Group type: EXPERIMENTAL
Intervention: Emergency Obstetric Care (EmOC) services
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Factors limiting access to EmOC services
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Cultural norms
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Health facilities' working hours
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Increase skilled female workers
Number of subjects: 170
Study: 16627214

Group type: EXPERIMENTAL
Intervention: Antox (combined antioxidant preparation containing selenium, betacarotene, L-methionine, vitamins C and E)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Antox
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14693733

Group type: EXPERIMENTAL
Intervention: Serum IGF‐I levels before biopsy
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: GST‐T1 variant alleles
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: IGF‐I variant alleles
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Age, ethnicity, total PSA, and DRE result
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Nine of 11 candidate genes
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: IGF‐I levels
Number of subjects: 1031
Study: 11014092

Group type: EXPERIMENTAL
Intervention: 99mTc injection (20‐40 MBq)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blue dye injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of 99mTc and blue dye
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Negative predictive value
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SN mapping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Micrometastasis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SN being the only nodal metastasis
Number of subjects: 40
Study: 8783666

Group type: EXPERIMENTAL
Intervention: Amifostine with 4‐hydroperoxycyclophosphamide (4‐HC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4‐hydroperoxycyclophosphamide (4‐HC) without amifostine
Number of subjects: 0
Study: 1464164

Group type: EXPERIMENTAL
Intervention: Rectal MST administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral MST administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral and Rectal MST administration
Number of subjects: 10
Study: 6389060

Group type: EXPERIMENTAL
Intervention: 50 g glucose with 50 g protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 g protein alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 g glucose alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 g glucose with 50 g protein (second meal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 g glucose (second meal)
Number of subjects: 0
Study: 31373418

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 60
Study: 29335629

Group type: EXPERIMENTAL
Intervention: Exergaming on Nintendo Wii®
Number of subjects: 42

Group type: COMPARATOR
Intervention: Classical physiotherapy (PT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups (Exergaming and PT)
Number of subjects: 42
Study: 27428595

Group type: EXPERIMENTAL
Intervention: Wearing high-heeled shoes for 2-5 years
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Wearing high-heeled shoes for 6-10 years
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Wearing high-heeled shoes for >20 years
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Wearing high-heeled shoes for <2 years
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Wearing high-heeled shoes for 11-20 years
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no high-heeled shoes)
Number of subjects: 137
Study: 24202408

Group type: EXPERIMENTAL
Intervention: MICA-TKA (minimal invasive and computer-assisted technique)
Number of subjects: 80

Group type: COMPARATOR
Intervention: MI-TKA (minimal invasive technique)
Number of subjects: 80
Study: 22144003

Group type: EXPERIMENTAL
Intervention: MENTHOL SPRAY
Number of subjects: 11

Group type: COMPARATOR
Intervention: CONTROL SPRAY
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON (no spray)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON-SPRAY (control spray)
Number of subjects: 11
Study: 20347088

Group type: EXPERIMENTAL
Intervention: 50-microg dose of misoprostol intravaginally 3 hours before oxytocin infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin infusion alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 16722027

Group type: EXPERIMENTAL
Intervention: Nocturnal intermittent peritoneal dialysis (NIPD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous cyclic peritoneal dialysis (CCPD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 11
Study: 15218994

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily for 42 days
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 10926790

Group type: EXPERIMENTAL
Intervention: 200 mg/day I‐3‐C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg/day I‐3‐C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9315044

Group type: EXPERIMENTAL
Intervention: Permethrin-treated curtains
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Permethrin-treated curtains (first year)
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Permethrin-treated curtains (second year)
Number of subjects: 90000
Study: 8395713

Group type: EXPERIMENTAL
Intervention: LMWH CY 216 (n = 35), subcutaneous injection, 6 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (n = 40), no specific treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LMWH CY 216 (n = 15 with preceding cerebral embolism)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (n = 7 with preceding cerebral embolism)
Number of subjects: 75
Study: 2944925

Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paykel's Clinical Interview for Depression, Brief Depression Rating Scale, Symptom Questionnaire (SQ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Contentment subscale of the SQ
Number of subjects: 40

Group type: COMPARATOR
Intervention: Depression subscale of the SQ
Number of subjects: 40
Study: 30252688

Group type: EXPERIMENTAL
Intervention: Plate expression
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Digital expression
Number of subjects: 17

Group type: COMPARATOR
Intervention: No expression
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All groups (including digital and no expression)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluorescein staining score
Number of subjects: 17
Study: 28558452

Group type: EXPERIMENTAL
Intervention: Tailor-made notched music therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Analogous sound masking (Control)
Number of subjects: 43
Study: 25996425

Group type: EXPERIMENTAL
Intervention: Single session laser photoablation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Two-session laser photoablation
Number of subjects: 29
Study: 23827881

Group type: EXPERIMENTAL
Intervention: Mercury exposure from dental amalgam tooth fillings
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Genetic variants of metallothionein (MT1M and MT2A)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Urinary Hg levels
Number of subjects: 507
Study: 21235759

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 305
Study: 19873910

Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy (Guanyuan (CV 4), Taixi (KI 3), Sanyinjiao (SP 6))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (antagonist scheme for ovulation induction without electroacupuncture)
Number of subjects: 60
Study: 17032148

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infusion
Number of subjects: 296

Group type: COMPARATOR
Intervention: Risedronate (RIS) 30 mg daily by mouth for 60 days
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Risedronate (RIS)
Number of subjects: 296
Study: 15863410

Group type: EXPERIMENTAL
Intervention: Cranberry juice (300 ml daily)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 376
Study: 12410197

Group type: EXPERIMENTAL
Intervention: Zinc-fortified ORS (40 mg/L)
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Zinc syrup (15 mg for 6-11 months; 30 mg for 12-35 months)
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Control (ORS only)
Number of subjects: 1219
Study: 9479341

Group type: EXPERIMENTAL
Intervention: ThinPrep Pap Test
Number of subjects: 16314
Study: 8789182

Group type: EXPERIMENTAL
Intervention: Optimal AV delay pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Worst AV delay pacing
Number of subjects: 19
Study: 2196354

Group type: EXPERIMENTAL
Intervention: Reduced manipulation protocol (n = 62)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard care (n = 94)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard manipulation
Number of subjects: 156
Study: 353085

Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sucrose-containing chewing gum
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 18
Study: 29794874

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1216
Study: 28747281

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (1-hour sessions twice daily for 10 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation (1-hour sessions twice daily for 10 weeks)
Number of subjects: 52
Study: 25526227

Group type: EXPERIMENTAL
Intervention: Once-daily, extended-release hydrocodone (Hysingla™ ER tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23580378

Group type: EXPERIMENTAL
Intervention: Computer-assisted collaborative care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21653932

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice a day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19539380

Group type: EXPERIMENTAL
Intervention: Intracapsular tonsillectomy/tonsillotomy (TT) (n=35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Regular tonsillectomy (TE) (n=32)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both TT and TE
Number of subjects: 67
Study: 16643698

Group type: EXPERIMENTAL
Intervention: TTM-based interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (standard midwifery advice and self-help leaflet)
Number of subjects: 0
Study: 14758575

Group type: EXPERIMENTAL
Intervention: Telemedicine examination
Number of subjects: 85

Group type: COMPARATOR
Intervention: In-person clinical examination
Number of subjects: 85